Cargando…
Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target
Adamantinomatous craniopharyngiomas (ACPs) are clinically challenging tumours, the majority of which have activating mutations in CTNNB1. They are histologically complex, showing cystic and solid components, the latter comprised of different morphological cell types (e.g. β-catenin-accumulating clus...
Ejemplares similares
-
SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma
por: Carreno, G, et al.
Publicado: (2019) -
CTNNB1 mutations are clonal in adamantinomatous craniopharyngioma
por: Apps, J. R., et al.
Publicado: (2020) -
Preclinical transgenic and patient‐derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma
por: Boult, Jessica K. R., et al.
Publicado: (2017) -
Characterization of the murine orthotopic adamantinomatous craniopharyngioma PDX model by MRI in correlation with histology
por: Hölsken, Annett, et al.
Publicado: (2018) -
Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma
por: Gonzalez-Meljem, Jose Mario, et al.
Publicado: (2017)